Konjac-mannan (glucomannan) improves glycemia and other associated risk
factors for coronary heart disease in type 2 diabetes. A randomized
controlled metabolic trial.
Diabetes Care. 1999 Jun;22(6):913-9.
Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E,
Brighenti F, Josse R, Leiter LA, Bruce-Thompson C.
Department of Nutritional Sciences, St. Michael's Hospital, Faculty
of Medicine, University of Toronto, Ontario, Canada. firstname.lastname@example.org
To examine whether Konjac-mannan (KJM) fiber improves metabolic control
as measured by glycemia, lipidemia, and blood pressure in high-risk
type 2 diabetic patients.
RESEARCH DESIGN AND METHODS:
A total of 11 hyperlipidemic and hypertensive type 2 diabetic patients
treated conventionally by a low-fat diet and drug therapy participated.
After an 8-week baseline, all were randomly assigned to take either
KJM fiber-enriched test biscuits (0.7 g/412 kJ [100 kcal] of glucomannan)
or matched placebo wheat bran fiber biscuits during two 3-week treatment
phases separated by a 2-week washout period. The diet in either case
was metabolically controlled and conformed to National Cholesterol Education
Program Step 2 guidelines, while medications were maintained constant.
Efficacy measures included serum fructosamine, lipid profiles, apolipoproteins,
blood pressure, body weight, and nutritional analysis.
Compared with placebo, KJM significantly reduced the metabolic control
primary end points: serum fructosamine (5.7%, P = 0.007, adjusted alpha
= 0.0167), total:HDL cholesterol ratio (10%, P = 0.03, adjusted alpha
= 0.05), and systolic blood pressure (sBP) (6.9%, P = 0.02, adjusted
alpha = 0.025). Secondary end points, including body weight, total,
LDL, and HDL cholesterol, triglycerides, apolipoproteins A-1, B, and
their ratio, glucose, insulin, and diastolic blood pressure, were not
significant after adjustment by the Bonferroni-Hochberg procedure.
KJM fiber added to conventional treatment may ameliorate glycemic control,
blood lipid profile, and sBP in high-risk diabetic individuals, possibly
improving the effectiveness of conventional treatment in type 2 diabetes.
Randomized Controlled Trial